Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New therapy aims to ease cancer Survivors' fear of return

NCT ID NCT06676228

Symptom relief Sponsor: Maltepe University Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study adapted a 6-session behavioral therapy called FORT for Turkish breast and ovarian cancer survivors to help them manage fear of cancer recurrence. Researchers worked with 100 participants to translate and test the therapy, measuring changes in fear, anxiety, and quality of life. The goal is to provide a culturally suitable tool to support survivors' mental health.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Fear of cancer recurrence therapy (FORT) - a 6-session behavioral intervention
What this could lead to
If successful, this culturally adapted therapy could provide an effective way to reduce fear of cancer recurrence and improve mental well-being for Turkish cancer survivors.
What could go wrong
This is a small, completed cultural adaptation study with 100 participants, so results may not apply broadly. The therapy's long-term benefits beyond 6 months are not yet known.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

100 people

The number who actually took part.

Started

Oct 2024

Finished

Sep 2025

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 65 years

Sex

Female participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Participants who are under 18 years of age * Participants whose primary treatment (chemotherapy, radiotherapy, surgery) has been completed (adjuvant treatment such as hormone therapy may be continued can be accepted into the study). * Participants with stage I-III breast cancer and ovarian cancer who have completed treatment less than 5 years ago and whose disease is in remission. * Participants who receive cut-off scores of 10 or above for the anxiety and 7 or above for the depression Hospital and Anxiety Scale. * Participants who score 4 for depression and 5 for anxiety and distress for the Emotion Thermometer. Exclusion Criteria: * Participants over 65 years of age * Participants who experience of recurrence/metastasis * Participants who has mental retardation * Participants who do not possess Turkish language skills * Participants who have another comorbid physical illness that causes disability * Participants who were diagnosed with a psychiatric disorder.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Anxiety are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

anxiety anxiety disorder breast cancer breast neoplasm cancerophobia depressive disorder ovarian cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Anxiety Cancer coping Depression not otherwise specified Fear of cancer recurrence Intolerance of uncertainty Quality of life (QOL) Self efficacy

Contacts and locations

Locations

  • Istanbul Maltepe University

    Istanbul, Turkey (Türkiye)

More trials for these conditions

Other studies related to the condition(s) this trial covers.